Clinical relevance of TRKA expression on neuroblastoma: Comparison with N-MYC amplification and CD44 expression

British Journal of Cancer

Volumn 75, Issue 8, 1997, Pages 1151-1155

  Combaret, V ^a   Gross, N ^b   Lasset, C ^a   Balmas, K ^b   Bouvier, R ^c   Frappaz, D ^a   Beretta Brognara, C ^b   Philip, T ^a   Favrot, M C ^a   Coll, J L ^a  

^a CENTRE LÉON BÉRARD   (France)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

CD44; Neuroblastoma; TRKA

Indexed keywords

HERMES ANTIGEN; NERVE GROWTH FACTOR RECEPTOR; RECEPTOR ANTIBODY;

AGE; ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; GANGLIONEUROMA; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NEUROBLASTOMA; ONCOGENE C MYB; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS;

EID: 8044227782     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.198     Document Type: Article

References (18)

1. Borrello MG, Bongarzone I, Pierotti MA, Luksch R, Gasparini M, Collini P, Pilotti S, Rizzetti MG, Mondellini P, De Bernardi B, Di Martino D, Garaventa A, Brisigotti M and Tonini GP (1993) Trk and ret proto-oncogene expression in human neuroblastoma specimens: high frequency of trk expression in non-advanced stages. Int J Cancer 54: 540-545
2. Brodeur GM, Azar C, Brother M, Hiemstra J, Kaufman B, Marshall H, Moley J, Nakagawara A, Saylors R, Scavarda N, Schneider S, Wasson J, White P, Seeger R, Look T and Castleberry R (1992) Neuroblastoma. Effect of genetic factors on prognosis and treatment. Cancer 70: 1685-1694
3. Combaret V, Wang Q, Favrot MC, Thiesse P, Philip I, Bouffet E, Bailly C, Bouvier R, Chauvin F, Zucker JM, Bernard JL, Lenoir G and Philip T (1989) Clinical value of N-myc oncogene amplification in 52 patients with neuroblastoma included in recent therapeutic protocols. Eur J Cancer Clin Oncol 24: 1607-1612
4. Combaret V, Gross N, Lasset C, Frappaz D, Peruisseau G, Philip T, Beck D and Favrot MC (1996) Clinical relevance of CD44 cell surface expression and Nmyc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. J Clin Oncol 14: 25-34
5. Donovan MJ, Hempstead BL, Horvath C, Chao MV and Schofield D (1993) Immunohistochemical localization of Trk receptor protein in pediatric small round blue cell tumors. Am J Pathol 143: 1560-1567
6. Evans AE, D'Angio GJ and Randolph J (1971) A proposed staging for children with neuroblastoma. Cancer 27: 374-378
7. Favrot MC, Combaret V, Goillot E, Lutz P, Frappaz D. Thiesse P. Thyss A, Dolbeau D, Bouffet E, Tabone E and Philip T (1991) Expression of integrin receptors on 45 clinical neuroblastoma specimens, Int J Cancer 49: 347-355
8. Favrot MC, Lasset C and Combaret V (1993) CD44: a new prognostic marker for neuroblastoma. N Engl J Med 329: 1965
9. Gross N, Beretta C, Peruisseau G, Jackson D, Simmons D and Beck D (1994) CD44H expression by human neuroblastoma cells: relation to MYCN amplification and lineage differentiation. Cancer Res 54: 4238-4242
10. Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
11. Kogner P, Barbany G, Dominici C, Castello MA, Raschella G and Persson H (1993) Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Res 53: 2044-2050
12. Mantel H and Haenzel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748
13. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB and Brodeur GM (1993) Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 328: 847-854
14. Philip T, Bernard JL, Zucker JM, Pinkerton R, Lutz P, Bordigoni P, Plouvier E, Robert A, Carton R, Philippe N, Philip I, Chauvin F and Favrot M (1987) High dose chemotherapy with bone marrow transplantation as consolidation treatment in neuroblastoma: an unselected group of stage IV patients over one year of age. J Clin Oncol 5: 266-271
15. Shimada H, Chatten J, Newton WA, Sachs N, Hamoudi AB, Chiba T, Marsden HB and Misuki K (1984) Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastomas and age-linked classification of neuroblastoma. J Natl Cancer Inst 73: 405-416
16. Susuki T, Bogenmann E, Shimada H, Stram D and Seeger RC (1993) Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst 85: 377-384
17. Tanaka T, Hiyama E, Sugimoto T, Sawada T, Tanabe M and Ida N (1995) TrkA gene expression in neuroblastoma. Cancer 76: 1086-1095
18. Zucker JM, Philip T, Bernard JL, Michon J, Bouffet E, Gentet JC, Lopez M, Coze C, Philip I, Bordigoni P, Plouvier E, Mazingue F and Vilcoq JR (1991) Single or double consolidation treatment according to remission status after initial therapy in metastatic neuroblastoma: first results of LMCE3 study in 40 patients. In Advances in Neuroblastoma Research, Evans A E, D'Angio G J, Knudson A G J and Seeder R C (eds). pp. 543-551. Wiley-Liss: New York